China’s Emerging Pillar Industries to Top 10 Trillion Yuan Output by End of 15th Five-Year Plan

The headline number is a planning target, not a market event — the more telling details are the IC output growth and the scale of drug licensing revenue, which suggest the emerging-industries push is already producing exportable intellectual property, not just domestic capacity. That matters for anyone tracking China's position in semiconductor supply chains and global pharma licensing. Whether the licensing momentum holds as more Chinese biotech assets reach overseas partners is the open question, alongside how much of the 10 trillion yuan target reflects new capacity versus reclassification of existing output.